Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
December 15, 2023
- Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
December 14, 2023
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Torii Scoops Up Japan Rights for Grass Pollinosis Med
December 14, 2023
- Avastin Biosimilars Add Malignant Glioma Indication in Japan
December 14, 2023
- Prograf Generics Now on Equal Footing with Original Product
December 14, 2023
- Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
December 13, 2023
- GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
December 13, 2023
- Total Sales of 26 Japan Drug Makers Up 6.1% in H1; Shionogi Nets Largest Growth
December 12, 2023
- Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- Lenvima-Keytruda Combo Misses Goal in 1st Line Endometrial Cancer
December 12, 2023
- NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
December 11, 2023
- KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
December 8, 2023
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Japan Ethical Drug Sales Up 8.4% in October: Crecon
December 8, 2023
- Keytruda Scores No. 1 in Japan Sales Ranking in November: Encise
December 8, 2023
- Daiichi Sankyo, Novartis Settle Patent Infringement Dispute Over Tafinlar
December 7, 2023
- CSL Launches Home Delivery Service for HAE Drug Berinert
December 7, 2023
- Abecma Approved for Earlier Lines of MM Therapy in Japan: BMS
December 7, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…